Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 19Glioma 5Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Ovarian Neoplasms 3Neuroblastoma 3Medulloblastoma 3Glioblastoma 3Colorectal Neoplasms 3Rhabdoid Tumor 2Lymphoma 2Lung Neoplasms 2Liposarcoma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Astrocytoma 2Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oligodendroglioma 1

Interventions

Cisplatin 9pembrolizumab 7Irinotecan 7Radiotherapy 6Fluorouracil 6Docetaxel 5spartalizumab 4Oxaliplatin 4130-nm albumin-bound paclitaxel 4Nivolumab 3Carboplatin 3toripalimab 2tislelizumab 2elgemtumab 2durvalumab 2Radiation 2Paclitaxel 2Leucovorin 2Gemcitabine 2Drug Therapy 2vandetanib 1tremelimumab 1ribociclib 1palbociclib 1obinutuzumab 1nedaplatin 1nazartinib 1naptumomab estafenatox 1liposomal doxorubicin 1dalpiciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Esophageal Squamous Cell Carcinoma × ribociclib × Clear all
NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis

Phase 1 Terminated
122 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡